Assess whether a CMC change is a comparability or a new product (3fd76c)

Situation

A CMC change is sits with regulatory-affairs lead because a boxed-warning proposal from the review division hit a safety team sitting on a new disproportionate signal. Evidence is CMC comparability package for a site change; write the Pharma & Life Sciences CMC and Development Pathways option that extract can carry.

Decision

Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose A CMC change is a comparability / A new product using CMC comparability package for a site change after a boxed-warning proposal from the review division.

Hypotheses to test

• Authorize A CMC change is a comparability now; CMC comparability package for a site change already has the discriminator after a boxed-warning proposal from the review division.
• Keep A new product in force until CMC comparability package for a site change is completed after a boxed-warning proposal from the review division for regulatory-affairs lead.
• Treat CMC comparability package for a site change as A CMC change is a comparability because both readings appear after a boxed-warning proposal from the review division.
• Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the page a CMC change is turns on in CMC comparability package for a site change.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether CMC comparability package for a site change supports the labeled claim regulatory-affairs lead would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a boxed-warning proposal from the review division and write the one fact that would move a CMC change is for regulatory-affairs lead.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for regulatory-affairs lead in a safety team sitting on a new disproportionate signal.